Astromech is bringing biological prediction and genetic-medicine design into one company through its $230 million all-stock acquisition of Form Bio, announced November 17, 2026. The aim is to connect clues from evolution with medicines researchers can build and test—and address manufacturing quality while those medicines are still being designed.
From evolutionary clues to buildable designs
Astromech’s models draw on biological data across species and evolutionary time. They seek to understand how biological functions emerged and predict how they may change. DNA sequences preserved over hundreds of millions of years can offer clues to important functions, providing a starting point for therapeutic design.
Form Bio supplies a different part of that process: AI tools for designing genetic medicines, improving gene therapy vectors and manufacturing, and assessing genomic quality. Its foundation models learn patterns in regulatory and coding DNA sequences from data, then apply those patterns to the design and development of human therapeutics.
The intended connection is between identifying a useful evolutionary pattern and designing a genetic construct that researchers can make and test. The companies see applications in human therapeutics, genome engineering and animal health. That scope extends beyond predicting what a sequence does to helping researchers decide what to build.
The companies aim to address quality problems during design, reducing unwanted components and potentially lessening the need for purification later. Better manufacturability is therefore part of the stated design objective, alongside biological function. Those benefits are goals for the integration, rather than demonstrated results from the newly combined operation.
Form Bio began by solving the computational challenges discovered from de-extinction and has grown into a company building foundation models for the design of human therapeutics.
Andrew Busey, Form Bio co-founder and former CEO, in the acquisition announcement
The quality results behind the pitch
Form Bio points to existing projects as evidence for its approach. In work with Cure Rare Disease on Duchenne muscular dystrophy, the company says promoter-sequence redesign increased full-genome content from 13% to 59% in less than 30 days. The announcement says that program has advanced to in vivo preclinical studies—testing in living organisms before clinical development.
In a separate program, Form Bio says coding-sequence optimization alone increased full-genome content from approximately 2% to approximately 45%, while expression stayed at baseline. The two examples concern different sequence changes. The second result specifically pairs a quality improvement with maintained expression, rather than claiming that both measures increased.
The announcement also names genetic-medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences that Form Bio’s capabilities support. Coave’s director of discovery science, Adrien Savy, said the platform helps his team rapidly evaluate and prioritize genetic constructs across multiple programs.
Assets and leadership move into Astromech
The transaction brings Form Bio’s intellectual property, selected contracts and assets, and team into Astromech. Both businesses belong to the Colossal Biosciences ecosystem. Form Bio launched in September 2022 after being developed within Colossal; Astromech emerged from Colossal’s work in comparative genomics, ancient DNA and computational biology.
Busey has been named Astromech’s Chief AI Officer and Head of Technology. The appointment puts Form Bio’s former chief executive in charge of AI and technology as its design tools and team join Astromech’s biological-modeling operation.
Reader comments
Newest comments first. Replies stay oldest first.